SYNERGISTIC DRUG COMPATIBILITY OF SUMATRIPTAN SUCCINATE AND METOCLOPRAMIDE HYDROCHLORIDE (IN SITU GEL FORMULATIONS) FOR NASAL DRUG RELEASE OPTIMIZATION
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i3.48485Keywords:
Sumatriptan Succinate, Metoclopramide Hydrochloride, SMP- Sumatriptan Succinate Metoclopramide Hydrochloride Polymer, Nasal drug delivery, Intranasal in-situ gels.Abstract
Objective: Migraine is a prevalent neurological condition that causes lifelong tenacious headaches and significantly impacts the daily lives of individuals. Despite being frequently underestimated or neglected, it affects the individual’s routine activities, performance, self-confidence, and identity. Treatment often involves the administration of painkillers, which can lead to various complications. This study aimed to develop and characterize an in situ nasal formulation of sumatriptan succinate and metoclopramide hydrochloride to enhance drug residence time in the nasal cavity and improve drug bioavailability.
Methods: Eight formulations of intranasal in situ gels were prepared using the “Cold Method” and evaluated for various parameters, including appearance, texture, viscosity, pH, gel strength, gelation temperature, drug content, and in vitro/ex vivo drug diffusion. FT-IR studies confirmed no interactions between sumatriptan succinate, metoclopramide hydrochloride, and the excipients. Simultaneous estimation method was used to evaluate drug content, in vitro and ex vivo drug diffusion.
Results: Among the formulations, “Sumatriptan Succinate Metoclopramide Hydrochloride Polymer (SMP8)” exhibited the most favorable characteristics. The percent cumulative drug release was determined to be 96.803±0.0015 for sumatriptan succinate and 92.569±0.0028 for metoclopramide hydrochloride, aligning with the Higuchi model kinetics. In vitro and ex vivo diffusion studies demonstrated that SMP8 provided sustained drug release for up to 9 h, making it the optimal dosage formulation for nasal drug delivery in the treatment of migraine.
Conclusion: This study’s findings suggest that the developed intranasal in situ gel formulation, SMP8, effectively releases sumatriptan succinate and metoclopramide hydrochloride over an extended period. By improving drug residence time and bioavailability, this formulation has the potential to enhance the therapeutic efficacy and patient compliance in the management of migraine.
Downloads
References
Kruja J. Headache in migrants and refugees. In: El Alaoui-Faris M, Federico A, Grisold W, editors. Neurology in Migrants and Refugees. Sustainable Development Goals Series. Cham: Springer; 2022. p. 229-38. doi: 10.1007/978-3-030-81058-0_19
Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: A retrospective analysis. BMC Neurol 2022;22:512. doi: 10.1186/s12883-022-03041-1, PMID 36585619
Gupta J, Gaurkar SS. Migraine: An underestimated neurological condition affecting billions. Cureus 2022;14:e28347. doi: 10.7759/ cureus.28347, PMID 36168353
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9. doi: 10.1212/01. wnl.0000252808.97649.21, PMID 17261680
Hsu YW, Liang CS, Lee JT, Chu HT, Lee MS, Tsai CL, et al. Associations between migraine occurrence and the effect of aura, age at onset, family history, and sex: A cross-sectional study. PLoS One 2020;15:e0228284. doi: 10.1371/journal.pone.0228284, PMID 32023286
Cady R, Schreiber C. Sumatriptan: Update and review. Expert Opin Pharmacother 2006;7:1503-14. doi: 10.1517/14656566.7.11.1503, PMID 16859433
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: A review on their therapeutic potential. J Pain Res 2018;11:515-26. doi: 10.2147/JPR.S132833, PMID 29563831
Landy S, Munjal S, Brand-Schieber E, Rapoport AM. Efficacy and safety of DFN-11 (Sumatriptan injection, 3 mg) in adults with episodic migraine: An 8-week open-label extension study. J Headache Pain 2018;19:70. doi: 10.1186/s10194-018-0882-y, PMID 30112725
Najjar M, Hall T, Estupinan B. Metoclopramide for acute migraine treatment in the emergency department: An effective alternative to opioids. Cureus 2017;9:e1181. doi: 10.7759/cureus.1181, PMID 28533997
Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, et al. Eletriptan in the management of acute migraine: An update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord 2016;9:414-23. doi: 10.1177/1756285616650619, PMID 27582896
Veronesi MC, Alhamami M, Miedema SB, Yun Y, Ruiz-Cardozo M, Vannier MW. Imaging of intranasal drug delivery to the brain. Am J Nucl Med Mol Imaging 2020;10:1-31. PMID 32211216
Reddy S, Tadi M. Nasal drug delivery system: A review. World J Pharm Res 2019;8:431-50.
Pandey A, Nikam A, Basavraj S, Mutalik S, Gopalan D, Kulkarni S, et al. Nose-to-brain drug delivery: Regulatory aspects, clinical trials, patents, and future perspectives. In: Direct Nose-to-Brain Drug Delivery. Vol. 1. United States: Academic Press; 2021. p. 495-522.
Awandekar NB, Dhawas SV, Tekade RD, Umekar MJ. Review on liposomal in-situ gel as a novel approach for nasal drug delivery system. J Glob Trends Pharm Sci 2021;12:9442-8.
Mahapatra AP, Saraswati R, Mahapatra AK, Patil RY, Panda KC. Formulation and evaluation of thermal induced intranasal in-situ gel of sumatriptan succinate. IOSR J Pharm 2020;10:16-26.
Panda K, Reddy A, Panda N, Reddy GN, Habibuddin M, Mahapatra A. Formulation and evaluation of thermosensitive intranasal in situ gel of sumatriptan succinate by using A blend of polymers. J Pharm Chem 2014;8:25-9.
Mishra SP, Jain AP. Formulation and evaluation of fast dissolving tablets of sumatriptan succinate. Int J Pharm Drug Res 2019;7:45-52.
Sayeed A, Pawan K, Areefulla Hussainy S. Formulation and evaluation of mouth dissolving tablets of metoclopramide HCl using natural and synthetic super disintegrants. Indo Am J Pharm Sci 2021;8:126-41.
Baghel P, Roy A, Chandrakar S, Bahadur S, Bhairam M. Formulation, optimization and evaluation of quick dispersible tablets of sumatriptan. J Appl Pharm Res 2019;7:9-16.
Weng J, Tong HH, Chow SF. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics 2020;12:732-50. doi: 10.3390/pharmaceutics12080732, PMID 32759786
Pathak R, Dash RP, Misra M, Nivsarkar M. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route. Acta Pharm Sin B 2014;4:151-60. doi: 10.1016/j. apsb.2014.02.002, PMID 26579378
Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol 2021;17:501-14. doi: 10.1038/s41582-021-00509-5, PMID 34145431
Weatherall MW. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 2015;6:115-23. doi: 10.1177/2040622315579627, PMID 25954496
Láinez MJ, García-Casado A, Gascón F. Optimal management of severe nausea and vomiting in migraine: Improving patient outcomes. Patient Relat Outcome Meas 2013;4:61-73. doi: 10.2147/PROM.S31392, PMID 24143125
Rettura F, Bronzini F, Campigotto M, Lambiase C, Pancetti A, Berti G, et al. Refractory gastroesophageal reflux disease: A management update. Front Med (Lausanne) 2021;8:765061. doi: 10.3389/ fmed.2021.765061, PMID 34790683
Martin V, Hoekman J, Aurora SK, Shrewsbury SB. Nasal delivery of acute medications for migraine: The upper versus lower nasal space. J Clin Med 2021;10:2468. doi: 10.3390/jcm10112468, PMID 34199479
Published
How to Cite
Issue
Section
Copyright (c) 2024 Mrs, Dr, Dr, Dr
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
